<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1844">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04530474</url>
  </required_header>
  <id_info>
    <org_study_id>1285242</org_study_id>
    <nct_id>NCT04530474</nct_id>
  </id_info>
  <brief_title>Outpatient Use of Ivermectin in COVID-19</brief_title>
  <official_title>Outpatient Use of Ivermectin in COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Temple University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Covid 19, a novel coronavirus, causes infection that, while mild to moderate in many people,&#xD;
      can lead to severe disease in a significant portion. Currently, it is expected that the&#xD;
      majority, 81%, of patients with COVID-19 will have mild to moderate disease, with 14% having&#xD;
      more severe disease (2). There exists a number of candidate drugs that may inhibit SARS-CoV-2&#xD;
      infection or progression of disease. Simple, safe and low-cost strategies that may be the&#xD;
      best solution to inhibit infection and limit transmission and spread of infection.&#xD;
&#xD;
      Ivermectin is a drug initially synthesized and used as an anthelmintic. It has been found to&#xD;
      have activity against several RNA viruses such as the SARS-CoV-2 by mechanisms that inhibit&#xD;
      importin α/β-mediated nuclear transport that may prevent viral proteins from entering the&#xD;
      nucleus to alter host cell function. A recent in vitro study showed that a single dose of&#xD;
      ivermectin could kill COVID-19 in vitro within 48 hours. A recent multi-continent&#xD;
      retrospective study of 1,400 patients demonstrated an association of ivermectin use with&#xD;
      lower in-hospital mortality 1.4% versus 8.5%. Given these findings and its safety profile,&#xD;
      cost and ease of administration, Ivermectin warrants study as a potential treatment to&#xD;
      prevent progression of COVID 19 infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Improvement</measure>
    <time_frame>28 days</time_frame>
    <description>Clinical Improvement as measured by a standardized scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Ivermectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 0.15-2 mg/kg/dose to a maximum of 12 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of 2-4 placebo pills</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin Pill</intervention_name>
    <description>Ivermecin as a one-time dose</description>
    <arm_group_label>Ivermectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive medication as a one time dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Symptoms highly suspicious for COVID-19.&#xD;
&#xD;
          2. Age at least 18 years&#xD;
&#xD;
          3. Negative pregnancy test for women of child bearing age&#xD;
&#xD;
          4. Able to consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history of Ivermectin allergy&#xD;
&#xD;
          2. Hypersensitivity to any component of Stromectol®&#xD;
&#xD;
          3. COVID-19 Pneumonia identified by chest X-ray or high resolution CT scan&#xD;
&#xD;
          4. Fever or cough present for more than 7 days&#xD;
&#xD;
          5. Positive IgG against SARS-CoV-2 by rapid test if available on baseline screening.&#xD;
&#xD;
          6. The following co-morbidities (or any other disease that, in the opinion of the&#xD;
             investigators, might interfere with the study:&#xD;
&#xD;
               1. Immunosuppression&#xD;
&#xD;
               2. HIV&#xD;
&#xD;
               3. Acute or chronic renal failure&#xD;
&#xD;
               4. Current neoplasm&#xD;
&#xD;
          7. Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 5 X upper limit&#xD;
             of normal within the prior 6 months if available OR clinical evidence of liver failure&#xD;
             with jaundice, ascites, encephalopathy.&#xD;
&#xD;
          8. Current use of CYP 3A4 or P-gp inhibitor drugs such as quinidine, amiodarone,&#xD;
             diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole,&#xD;
             ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. Use of&#xD;
             critical CYP3A4 substrate drugs such as warfarin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Derek Isenberg, MD</last_name>
    <phone>2157078020</phone>
    <email>derek.isenberg@tuhs.temple.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nina Gentile, MD</last_name>
    <phone>2157078020</phone>
    <email>nina.gentile@temple.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Derek Isenberg, MD</last_name>
      <phone>215-707-8020</phone>
      <email>derek.isenberg@tuhs.temple.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nina Gentile, MD</last_name>
      <phone>215-707-8020</phone>
      <email>nina.gentile@tuhs.temple.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IVERMECTIN</keyword>
  <keyword>COVID</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

